SCHEMBL1203885

SCHEMBL1203885

CCOC(=O)c1cccc(N(C)C(=O)c2cnc3ccc(N(C)Cc4ccc(OC)cc4)nn23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPBWR1 P48145 1/20 0.39
▸ MCHR1 Q99705 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ TBXAS1 P24557 1/20 0.39
▸ DYRK3 O43781 1/20 0.38
▸ CCNT1 O60563 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ DYRK2 Q92630 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ FYN P06241 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203271 0.85 KMT2A (0.48) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL1203715 0.85 PIM1 (0.49) MAOBDYRK3CCNT1CCNA2CDK2
SCHEMBL1203883 0.84 MAPT (0.41) MEN1KMT2ANPBWR1MCHR1TBXAS1
SCHEMBL1203587 0.83 DYRK3 (0.45) MEN1KMT2ANPBWR1MCHR1DYRK3
SCHEMBL1203565 0.79 DYRK3 (0.36) NPBWR1MCHR1DYRK3CCNT1CCNA2
SCHEMBL1202379 0.77 NTRK1 (0.47) MEN1KMT2AFYNMAPTLMNA
SCHEMBL1203202 0.76 NTRK1 (0.46) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL1202900 0.71 PPARD (0.46) MEN1KMT2AFYNMAPTLMNA
SCHEMBL1203558 0.69 KDM4E (0.47) KMT2ADYRK1AMAPTNTRK1NTRK3
SCHEMBL1203076 0.69 PIM1 (0.51) MEN1KMT2ADYRK3CCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 MEN1 2279/4885KMT2A 1247/4885NPBWR1 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback